EZH2 and cancer: DNA methyltransferase inhibitor (5-Azacytidine) treatment partially decreased the methylation level in the promoter region of WNT2 (Fig. 5d) and increased EZH2 binding (Fig. 5e), leading to the attenuation of WNT2 expression in cancer cells (Fig. 5f).